BMS MULTICENTER ARIPIPRAZOLE DLW STUDY

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 该项目旨在量化精神分裂症患者在奥氮平或齐拉西酮前瞻性随机治疗12周期间治疗引起的总能量消耗(TEE)、活动能量消耗(AEE)和能量摄入(ET)的变化。该项目将在奥氮平和齐拉西酮治疗的受试者中提供DLW测量，这是一项正在进行的由R01资助的关于四种不同抗精神病药物代谢影响的较大研究(PI：新人，MH#063985-05，GCRC批准的方案：811.2)。根据奥氮平的显著体重增加效应和齐拉西酮的最小效应，选择奥氮平和齐拉西酮治疗的受试者进行DLW测量，以获得使用这一方法学评估抗精神病药物对卡路里摄入量和活动水平的影响的初步数据。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This project aims to quantify treatment-induced changes in Total Energy Expenditure (TEE), Activity Energy Expenditure (AEE), and Energy Intake (ET) in schizophrenia patients during twelve weeks of prospective, randomized treatment with either olanzapine or ziprasidone. This project will provide for DLW measurements in a subject of the olanzapine- and ziprasidone-treated subjects in an ongoing larger R01-funded study of the metabolic effects of four different antipsychotic agents (PI: Newcomer, MH #063985-05, GCRC approved protocol: 811.2). Olanzapine and ziprasidone treated subjects are selected for DLW measurements based on the prominent weight gain effects of olanzapine and the minimal effects of ziprasidone, in order to obtain pilot data on the use of this methodology to assess the effects of antipsychotics on caloric intake and activity level.